Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MACRT: MSL-109 for CMV Retinitis
NCT00000135Phase 3Completed
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
- Start
- Sep 1995
- Primary completion
- Aug 1996
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial in cytomegalovirus retinitis comparing MSL-109 with Placebo (2 arms). Primary endpoint: Mortality Rate at 17 months. Started Sep 1995; status: completed.
02
Drugs
sevirumab
03
Conditions
cytomegalovirus retinitis
Beyond the preview
Go deeper on NCT00000135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000135.